You have read all your free articles, to continue reading subscribe to read the rest of this content.
The two companies are now supplying Ximluci (ranibizumab biosimilar) in England via a National Health Service (NHS) England Framework Agreement. The partners announced in January 2023 that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) had granted a marketing authorization Already a subscriber Login You have read all your…
AstraZeneca’s Symbicort Turbuhaler has been approved in China as an anti-inflammatory reliever to be taken as-needed in response to symptoms to achieve asthma control in patients with mild asthma aged 12 years and older. The approval by the National Medical Products Administration (NMPA) was baAlready a subscriber Login You have…
Imfinzi has been approved in China for the 1st-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), in combination with standard of care platinum chemotherapy (etoposide plus a choice of either carboplatin or cisplatin). “Today’s approval of Imfinzi plus cheAlready a subscriber Login You have read all…
In our upcoming issue of Nordic Life Science, Thomas Lönngren, former head of the EMA, emphasizes five important hurdles to identify for the pharmaceutical sector. Thomas Lönngren’s years from the regulatory side and the last ten years as a consultant have provided him with a proper global ovAlready a subscriber…
